HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N,N',N'- tris(2- hydroxyethyl)- 1,3,5- benzenetricarboxamide

a TrkB ligand

Also Known As:

LM22A-4

Networked: 12 relevant articles (3 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Yang, Tao: 3 articles (01/2022 - 07/2012)
2.	Fletcher, Jessica L: 3 articles (09/2021 - 01/2019)
3.	Murray, Simon S: 3 articles (09/2021 - 01/2019)
4.	Wood, Rhiannon J: 3 articles (09/2021 - 01/2019)
5.	Longo, Frank M: 2 articles (01/2022 - 07/2012)
6.	Dill, Larissa K: 2 articles (09/2021 - 01/2021)
7.	Robertson, Kate: 2 articles (09/2021 - 01/2021)
8.	Semple, Bridgette D: 2 articles (09/2021 - 01/2021)
9.	Wang, Sharon: 2 articles (09/2021 - 01/2021)
10.	Zamani, Akram: 2 articles (09/2021 - 01/2021)

Related Diseases

1.	Seizures (Absence Seizure) 01/01/2020 - "Here, the antiseizure efficacy of TrkB agonists LM22A-4, HIOC, and deoxygedunin (DG) on PB-refractory seizures and postischemic TrkB pathway activation was investigated in a mouse model (CD-1, P7) of refractory neonatal seizures. " 01/01/2022 - "To test this hypothesis, we treated DS mice with LM22A-4 (LM), a partial agonist at the BDNF TrkB receptor, for 7 d starting at postnatal day 13 (P13), before the onset of spontaneous seizures. "
2.	Stroke (Strokes) 07/01/2012 - "LM22A-4 treatment significantly improved limb swing speed and accelerated the return to normal gait accuracy after stroke. " 07/01/2012 - "LM22A-4 or its derivatives might therefore serve as "pro-recovery" therapeutic agents for stroke." 07/01/2012 - "LM22A-4 treatment also doubled both the number of new mature neurons and immature neurons adjacent to the stroke. " 07/01/2012 - "Beginning 3 days after stroke, mice received LM22A-4 or saline vehicle daily for 10 weeks. "
3.	Apnea 09/01/2014 - "In vivo, acute treatment of Mecp2-null and -heterozygous mutants with LM22A-4 completely eliminated spontaneous apneas in resting animals, without sedation. "
4.	Ischemic Optic Neuropathy (Anterior Ischemic Optic Neuropathy) 12/01/2018 - "TrkB receptor partial agonist LM22A-4 promoted survival of cultured RGCs in vitro by TrkB receptor activation, and treatment in vivo led to increased survival of RGCs after optic nerve ischemia, providing support that LM22A-4 may be effective therapy to treat ischemic optic neuropathy. " 12/01/2018 - "In this study, we tested the effects of LM22A-4, a small molecule TrkB receptor-specific partial agonist, on RGC survival in vitro and in experimental nonarteritic anterior ischemic optic neuropathy (AION), the most common acute optic neuropathy in those older than 50 years. "
5.	Spinal Cord Injuries (Spinal Cord Injury) 01/01/2015 - "This study provides an experimental evidence that LM22A-4 reduces the development of tissue injury associated with spinal cord trauma, and activation of the activity of TrkB may represent a novel approach for the therapy of spinal cord trauma." 01/01/2015 - "The goal of this study was to elucidate the protection by and potential mechanisms of LM22A-4, a specific agonist of tyrosine kinase receptor B, against spinal cord injury (SCI). "

Related Drugs and Biologics

1.	deoxygedunin
2.	trkB Receptor
3.	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)
4.	Brain-Derived Neurotrophic Factor (BDNF)
5.	Annexin A5
6.	Anti-Anxiety Agents (Anxiolytics)
7.	Retinaldehyde (Retinal)
8.	Peptides (Polypeptides)
9.	Nerve Growth Factors (Neurotrophins)
10.	Cuprizone

Related Therapies and Procedures

1.	Therapeutics